openPR Logo
Press release

Trigeminal Neuralgia Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Noema Pharma AG, Biohaven Pharmaceuticals, Biogen, Eli Lilly and Company, Novartis

07-13-2023 01:35 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Trigeminal Neuralgia Market Report 2032: Epidemiology Data,

DelveInsight's "Trigeminal Neuralgia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Trigeminal Neuralgia, historical and forecasted epidemiology as well as the Trigeminal Neuralgia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Trigeminal Neuralgia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Trigeminal Neuralgia Market Forecast
https://www.delveinsight.com/sample-request/trigeminal-neuralgia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Trigeminal Neuralgia Market Report:
• The Trigeminal Neuralgia market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• The National Organisation for Rare Disorders (NORD) reports that women are slightly more likely than men to experience trigeminal neuralgia.
• Although the actual incidence is unknown, the United States sees between 10,000 and 15,000 new cases annually
• According to a study by Lambru et al. (2020), the yearly incidence of TN is projected to be 4-29 per 100 000 person-years, while the lifetime prevalence is estimated to be 0.16%-0.3%. Women are more likely than men to have it
• According to estimates, there are 5.5 cases of Trigeminal Neuralgia (with a 95% confidence interval of 4.7 to 6.4) for every 100,000 person-years. From 0.1 in 0 to 19-year-olds to 23.1 per 100,000 person-years in those 80 and older, the incidence rose with age.
• Key Trigeminal Neuralgia Companies: Noema Pharma AG, Biohaven Pharmaceuticals, Biogen, Eli Lilly and Company, Novartis, and others
• Key Trigeminal Neuralgia Therapies: Basimglurant, Rimegepant, CNV1014802, Galcanezumab, COA566, and others
• The Trigeminal Neuralgia epidemiology based on gender analyzed that Trigeminal Neuralgia (TN) incidence is more common in females in comparison to males
The Trigeminal Neuralgia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Trigeminal Neuralgia pipeline products will significantly revolutionize the Trigeminal Neuralgia market dynamics.

Trigeminal Neuralgia Overview
The trigeminal nerve, or fifth cranial nerve, is one of the most extensively dispersed nerves in the head and is affected by the chronic pain syndrome known as trigeminal neuralgia (TN), sometimes known as tic douloureux. It falls within the category of neuropathic pain, which can be divided into two categories: primary (idiopathic) and secondary.

Get a Free sample for the Trigeminal Neuralgia Market Report
https://www.delveinsight.com/report-store/trigeminal-neuralgia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Trigeminal Neuralgia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Trigeminal Neuralgia Epidemiology Segmentation:
The Trigeminal Neuralgia market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Trigeminal Neuralgia
• Prevalent Cases of Trigeminal Neuralgia by severity
• Gender-specific Prevalence of Trigeminal Neuralgia
• Diagnosed Cases of Episodic and Chronic Trigeminal Neuralgia

Download the report to understand which factors are driving Trigeminal Neuralgia epidemiology trends @ Trigeminal Neuralgia Epidemiology Forecast
https://www.delveinsight.com/sample-request/trigeminal-neuralgia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Trigeminal Neuralgia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Trigeminal Neuralgia market or expected to get launched during the study period. The analysis covers Trigeminal Neuralgia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Trigeminal Neuralgia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Trigeminal Neuralgia Therapies and Key Companies
• Basimglurant: Noema Pharma AG
• Rimegepant: Biohaven Pharmaceuticals
• CNV1014802: Biogen
• Galcanezumab: Eli Lilly and Company
• COA566: Novartis

Discover more about therapies set to grab major Trigeminal Neuralgia market share @ Trigeminal Neuralgia Treatment Market
https://www.delveinsight.com/sample-request/trigeminal-neuralgia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of the Trigeminal Neuralgia Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Trigeminal Neuralgia Companies: Noema Pharma AG, Biohaven Pharmaceuticals, Biogen, Eli Lilly and Company, Novartis, and others
• Key Trigeminal Neuralgia Therapies: Basimglurant, Rimegepant, CNV1014802, Galcanezumab, COA566, and others
• Trigeminal Neuralgia Therapeutic Assessment: Trigeminal Neuralgia current marketed and Trigeminal Neuralgia emerging therapies
• Trigeminal Neuralgia Market Dynamics: Trigeminal Neuralgia market drivers and Trigeminal Neuralgia market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Trigeminal Neuralgia Unmet Needs, KOL's views, Analyst's views, Trigeminal Neuralgia Market Access and Reimbursement

To know more about Trigeminal Neuralgia companies working in the treatment market, visit @ Trigeminal Neuralgia Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/trigeminal-neuralgia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Trigeminal Neuralgia Market Report Introduction
2. Executive Summary for Trigeminal Neuralgia
3. SWOT analysis of Trigeminal Neuralgia
4. Trigeminal Neuralgia Patient Share (%) Overview at a Glance
5. Trigeminal Neuralgia Market Overview at a Glance
6. Trigeminal Neuralgia Disease Background and Overview
7. Trigeminal Neuralgia Epidemiology and Patient Population
8. Country-Specific Patient Population of Trigeminal Neuralgia
9. Trigeminal Neuralgia Current Treatment and Medical Practices
10. Trigeminal Neuralgia Unmet Needs
11. Trigeminal Neuralgia Emerging Therapies
12. Trigeminal Neuralgia Market Outlook
13. Country-Wise Trigeminal Neuralgia Market Analysis (2019-2032)
14. Trigeminal Neuralgia Market Access and Reimbursement of Therapies
15. Trigeminal Neuralgia Market Drivers
16. Trigeminal Neuralgia Market Barriers
17. Trigeminal Neuralgia Appendix
18. Trigeminal Neuralgia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:
Trigeminal Neuralgia Pipeline https://www.delveinsight.com/report-store/trigeminal-neuralgia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Trigeminal Neuralgia Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Trigeminal Neuralgia market. A detailed picture of the Trigeminal Neuralgia pipeline landscape is provided, which includes the disease overview and Trigeminal Neuralgia treatment guidelines.
Trigeminal Neuralgia Epidemiology https://www.delveinsight.com/report-store/trigeminal-neuralgia-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Trigeminal Neuralgia Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Trigeminal Neuralgia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight

Monkeypox Market https://www.delveinsight.com/report-store/monkeypox-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Monkeypox Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Pars Planitis Market
https://www.delveinsight.com/report-store/pars-plantis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products

Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market https://www.delveinsight.com/report-store/zika-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Opioid Use Disorder Market https://www.delveinsight.com/report-store/opioid-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Opioid Use Disorder (OUD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Trigeminal Neuralgia Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Noema Pharma AG, Biohaven Pharmaceuticals, Biogen, Eli Lilly and Company, Novartis here

News-ID: 3128881 • Views:

More Releases from DelveInsight Business Research

Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibrillation Space by DelveInsight
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals. Objective of the Case Study The
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestones, Therapies in Development, Mechanisms of Action, and Routes of Administration - By DelveInsight
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics. According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Rising Cancer Burden and Technological Advancements, states DelveInsight
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies. Biopsy devices play a crucial role in disease diagnosis by
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven by Rising Surgical Procedures, Technological Advancements, and Growing Adoption of Minimally Invasive Techniques, States DelveInsight
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide. DelveInsight's General Surgery Devices Market Report 2032 provides

All 5 Releases


More Releases for Trigeminal

Trigeminal Neuralgia Treatment Market Size, Trigeminal Neuralgia Treatment Marke …
Trigeminal Neuralgia Treatment Market Dynamics are clarified by an in-depth review of facts on current and emerging trends. To understand a resource, the paper uses Porter's five forces to examine the importance of numerous qualities such as understanding of suppliers and customers, dangers provided by various agents, competitive strength, and promising new businesses. precious. Furthermore, the study covers numerous firms' Trigeminal Neuralgia Treatment research data, benefit, gross margin, worldwide market
Trigeminal Neuralgia - Drug Pipeline Landscape, 2022
Trigeminal Neuralgia (TN), also known as tic douloureux, is a condition that causes painful sensations similar to an electric shock on one side of the face. The pain typically involves the lower face and jaw, although sometimes it affects the area around the nose and above the eye. There are two types of TN primary and secondary. Primary trigeminal Neuralgia has been linked to the compression of the nerve. Trigeminal Neuralgia
Trigeminal Neuralgia Treatment Medicine Market: Competitive Dynamics & Global Ou …
LP INFORMATION recently released a research report on the Trigeminal Neuralgia Treatment Medicine market analysis, which studies the Trigeminal Neuralgia Treatment Medicine's industry coverage, current market competitive status, and market outlook and forecast by 2025. Global "Trigeminal Neuralgia Treatment Medicine Market 2020-2025" Research Report categorizes the global Trigeminal Neuralgia Treatment Medicine market by key players, product type, applications and regions,etc. The report also covers the latest
Trigeminal Neuralgia Treatment Market to Witness Robust Expansion by 2024
LP INFORMATION offers a latest published report on Trigeminal Neuralgia Treatment Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. According to this study, over the next five years the Trigeminal Neuralgia Treatment market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019.
Trigeminal Neuralgia Treatment Market Opportunity Analysis, to 2026
Trigeminal neuralgia (TN), also known as tic douloureux, is a chronic pain disorder that affects the fifth cranial or trigeminal nerve. It causes inflammatory conditions due to systemic diseases including Lyme disease, sarcoidosis, and multiple sclerosis. There is also an association with collagen vascular diseases including systemic lupus erythematosus and scleroderma. The condition is treated on an outpatient basis, except till neurosurgical intervention is required. Its management must be customized
Global Trigeminal Neuralgia (TN) Therapeutics Market
Trigeminal neuralgia occurs when the functioning of the trigeminal nerve is disrupted due to damage of the nerve. Trigeminal neuralgia is a chronic condition resulting in intense and extreme pain in the face and is more common among females. The incident represents electrical shock-like feeling and lasts from few seconds to minutes. The etiology of trigeminal neuralgia includes compression of blood vessels, degeneration of arteries, myelin sheath infiltration and idiopathic.